Dr. Shaw on Alectinib as First-Line Therapy in Lung Cancer

Dr. Shaw on Alectinib as First-Line Therapy in Lung Cancer

ALEX: alectinib is the best first-line therapy available for ALK-positive NSCLCПодробнее

ALEX: alectinib is the best first-line therapy available for ALK-positive NSCLC

Phase 3 ALEX Study: Comparing Alecensa to Xalkori in ALK+ Lung CancerПодробнее

Phase 3 ALEX Study: Comparing Alecensa to Xalkori in ALK+ Lung Cancer

Alectinib eclipses crizotnib for ALK positive lung cancerПодробнее

Alectinib eclipses crizotnib for ALK positive lung cancer

Avelumab in combinations for lung cancer and update from ALEX studyПодробнее

Avelumab in combinations for lung cancer and update from ALEX study

Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLCПодробнее

Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC

Segment 2: Molecular Targets in NSCLCПодробнее

Segment 2: Molecular Targets in NSCLC

Keynote Lecture: Targeted Therapies in Lung Cancer 2.0 – Advances and PromisesПодробнее

Keynote Lecture: Targeted Therapies in Lung Cancer 2.0 – Advances and Promises

Dr. Shaw Discusses LDK378 and Alectinib (AF802) for ALK-Positive NSCLCПодробнее

Dr. Shaw Discusses LDK378 and Alectinib (AF802) for ALK-Positive NSCLC

Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung CancerПодробнее

Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer

Next-Generation ALK Inhibitors for NSCLCПодробнее

Next-Generation ALK Inhibitors for NSCLC